InMode (INMD) Ownership - Who owns InMode?

Key Takeaways

• INMD is the Nasdaq-listed ticker for InMode Ltd., an Israel-based medical device maker specializing in energy-based aesthetic and medical treatments.
• The company's products use proprietary radio frequency (RF) technology for minimally invasive, non-invasive, and hands-free procedures across plastic surgery, dermatology, gynecology, and ophthalmology.
• InMode operates a "razor-and-blade" business model, generating revenue from both capital equipment sales and recurring consumables and service.
• The company sells primarily through a direct sales force, with a growing international footprint alongside its historically large U.S. business.
• InMode is known for high gross margins and a strong cash position, but operates in a discretionary, economically sensitive market.

Introduction

InMode Ltd. is a global medical technology company that designs, develops, manufactures, and markets energy-based devices for aesthetic and medical treatments. Traded on the Nasdaq Global Select Market under the ticker INMD, the company has become one of the more recognizable names in the medical aesthetics industry. Investors follow InMode for its proprietary radio frequency (RF) technology, its direct-sales distribution model, and a financial profile characterized by unusually high gross margins relative to many medical device peers.

Company Profile

InMode was incorporated on January 2, 2008, and is headquartered in Yokne'am, Israel. The company was formerly known as Invasix Ltd. before changing its name to InMode Ltd. in November 2017. It has traded on Nasdaq since August 2019. The company was co-founded by Moshe Mizrahy, who serves as Chief Executive Officer, and Dr. Michael Kreindel, its Chief Technology Officer.

InMode's core technology is built on proprietary radio frequency assisted lipolysis and deep subdermal fractional RF technology. Radio frequency energy is used to heat tissue beneath the skin, enabling procedures such as body contouring, skin tightening, and facial rejuvenation. The company's product portfolio is organized around three broad categories:

• Minimally invasive platforms — used for liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation.
• Non-invasive platforms — targeting procedures such as permanent hair reduction, wrinkle reduction, and treatment of pigmented lesions.
• Hands-free platforms — focused on skin tightening, fat reduction, and muscle stimulation.

Well-known product platforms in the InMode portfolio include BodyTite, Morpheus8, Votiva, Contoura, EvolveX, Evoke, and EmpowerRF. These devices are used across plastic surgery, dermatology, gynecology, otolaryngology (ENT), and ophthalmology practices.

Business Model and Revenue Sources

InMode's business model resembles a classic razor-and-blade approach. The company sells capital equipment — its RF-based platforms — to physicians, clinics, and medical spas, and then generates recurring revenue from single-use consumables, extended warranties, and service. This structure means that a portion of revenue is tied to the installed base of devices, providing a degree of recurring, high-margin income beyond one-time equipment sales.

Historically, capital equipment has represented the large majority of InMode's revenue, with consumables and service contributing a smaller but recurring share. The company's financial profile is notable for gross margins that have frequently approached 80%, reflecting the value of its proprietary technology and the relatively low cost of the consumables it sells.

Geographically, InMode has long relied on the United States as its largest market, but it has steadily expanded its international presence through wholly owned subsidiaries across North America, Europe, Asia, and Latin America, as well as distributor partnerships in other regions. The company sells most of its products through a direct sales force, a strategy that allows it to capture more of the value of each sale and maintain closer relationships with physician customers.

Why Investors Follow INMD

Several factors draw investor attention to InMode. First, its proprietary RF technology and a broad product portfolio position it as a meaningful competitor in the growing medical aesthetics market, which spans both medical practices and consumer-facing aesthetics. Second, its razor-and-blade revenue model creates a recurring stream of consumables sales that scales with the installed base of devices.

InMode also stands out for its financial characteristics. The company has maintained high gross margins, a strong balance sheet with substantial cash, and a history of returning capital to shareholders through share repurchases. Its ongoing investment in research and development — including new platform launches and expanded indications across ophthalmology and ENT — represents a potential long-term growth driver as it seeks to address new medical specialties.

Risks and Important Considerations

InMode operates in a discretionary, economically sensitive market. Demand for aesthetic procedures can weaken when consumer confidence declines or when financing for equipment purchases becomes more expensive, which can pressure both capital equipment sales and procedure volumes. The company's U.S. business in particular has shown sensitivity to macroeconomic conditions and shifts in the aesthetic industry.

Other considerations include intense competition in the medical aesthetics space, regulatory requirements across many countries, and the company's exposure to geopolitical conditions in Israel, where its operations are headquartered. Changes in tariffs and supply-chain conditions can also affect margins. Finally, because a significant share of revenue comes from capital equipment, results can fluctuate from quarter to quarter depending on the timing of purchases by physicians and clinics.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Exploring tools like the AI Screener can help you build a more systematic approach to finding and evaluating potential investments.

Conclusion

InMode Ltd. has established itself as a distinctive player in medical aesthetics by combining proprietary radio frequency technology with a direct-sales model and a razor-and-blade revenue structure. Its broad product portfolio across multiple medical specialties, high-margin financial profile, and expanding international footprint make it a company worth understanding for investors interested in healthcare and medical technology. At the same time, its exposure to discretionary consumer spending and a competitive, regulated industry underscores the importance of evaluating both the opportunities and the risks that define this business.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations